Abstract
Three thousand fifty four children with NCI SR ALL were enrolled on CCG-1991; 2075 eligible patients were randomized and began treatment with intrathecal cytarabine, vincristine (V), dexamethasone (DX), and pegylated asparaginase (ASP). Bone marrow status was assessed at Day 7 and 14, and 28 of Induction. Slow early responders (SER’s) (Day 7/14 M3-M3, or M3-M2; and M2 at Day 28 Induction) received rescue daunorubicin and were assigned to augmented BFM therapy (
N Engl J Med
1998
; 338
:1663
. | Time Point 1 . | Time Point 2 . | Time Point 3 . |
---|---|---|---|
MRD . | Day 14 (Induction Day 14) . | Day 28 (RER) or 35 (SER) (End Induction) . | Day 84 (RER) or 119 (SER) (Interim Maintenance Day 28) . |
*Sensitivity < 0.01% | |||
“absolute” negative* | 1/44 | 13/340 | 15/350 |
low positive < 0.01% | 1/27 | 8/89 | 5/50 |
positive 0.01 %–0.1% | 6/87 | 6/104 | 3/37 |
positive 0.1%–1% | 6/91 | 4/43 | 4/9 |
positive > 1% | 6/67 | 7/21 | 1/1 |
total | 20/316 | 45/597 | 30/448 |
. | Time Point 1 . | Time Point 2 . | Time Point 3 . |
---|---|---|---|
MRD . | Day 14 (Induction Day 14) . | Day 28 (RER) or 35 (SER) (End Induction) . | Day 84 (RER) or 119 (SER) (Interim Maintenance Day 28) . |
*Sensitivity < 0.01% | |||
“absolute” negative* | 1/44 | 13/340 | 15/350 |
low positive < 0.01% | 1/27 | 8/89 | 5/50 |
positive 0.01 %–0.1% | 6/87 | 6/104 | 3/37 |
positive 0.1%–1% | 6/91 | 4/43 | 4/9 |
positive > 1% | 6/67 | 7/21 | 1/1 |
total | 20/316 | 45/597 | 30/448 |
Disclosures: Matloub:bristol-myers squibb: Employment. Gaynon:Enzon: Speakers Bureau.
Author notes
Corresponding author
2008, The American Society of Hematology
2008